PropertyValue
?:abstract
  • Orientações para acesso ao medicamento HIDROXICLOROQUINA, mediante cadastro no Componente Especializado da Assistência Farmacêutica – CEAF, para pacientes portadores de doenças autoimunes: Lúpus Eritematoso e Artrite Reumatoide;e portadores de miopatias inflamatórias: Dermatomiosite e Polimiosite
?:creator
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Comunicado - SGAIS/SES-RJ NO 02/2020 RIO DE JANEIRO, 25 DE MARÇO DE 2020
?:type
?:who_covidence_id
  • #743555
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/4mkd9vt3>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/4mkd9vt3>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all